Metabolite | HPLC RT† (min) | Peak Identification‡ | Percentage of Total Dose in Urine | ||
---|---|---|---|---|---|
Oral (200 mg/kg) | Dermal (250 mg/kg) | Intravenous (20 mg/kg) | |||
Undefined | 11 | A | 2.0 | ||
Undefined | 16 | B | 4.5 | 2.3 | |
Undefined | 22 | C | 8.5 | 3.8 | |
N-benzyl-l-glycine | 24 | D | 19.1 | 7.8 | 14.8 |
Undefined | 25 | E | 9.2 | ||
N-phenylacetyl-l-glycine | 26 | F | 35.1 | 8.7 | 24.5 |
Undefined | 32 | G | 4.1 | 2.2 | 10.0 |
N-acetyl-S-(4-phenyl-2-butanone)-l-cysteine | 34 | H | 6.7 | 1.7 | 9.9 |
Undefined | 41 | J | 2.3 | ||
Methyl styryl ketone | 52 | K1 | 8.6 | 4.4 | 14.6 |
Methyl styryl carbinol | 52 | K2 | <0.1 | <0.1 | <0.1 |
Total % dose in urine | 86.6% | 30.6% | 87.6% |
Pooled urine samples (0 to 24 hr) from three rats per route of administration.
† HPLC retention time.
‡ Fig. 7.